Abstract:Chronic inflammation triggers development of metabolic disease, and pulmonary tuberculosis (TB) generates chronic systemic inflammation. Whether TB induced-inflammation impacts metabolic organs and leads to metabolic disorder is ill defined. The liver is the master regulator of metabolism and to determine the impact of pulmonary TB on this organ we undertook an unbiased mRNA and protein analyses of the liver in mice with TB and reanalysed published data on human disease. Pulmonary TB led to upregulation of genes in the liver related to immune signalling and downregulation of genes encoding metabolic processes. In liver, IFN signalling pathway genes were upregulated and this was reflected in increased biochemical evidence of IFN signalling, including nuclear location of phosphorylated Stat-1 in hepatocytes. The liver also exhibited reduced expression of genes encoding the gluconeogenesis rate-limiting enzymes Pck1 and G6pc. Phosphorylation of CREB, a transcription factor controlling gluconeogenesis was drastically reduced in the livers of mice with pulmonary TB as was phosphorylation of other glucose metabolism-related kinases, including GSK3a, AMPK, and p42. In support of the upregulated IFN signalling being linked to the downregulated metabolic functions in the liver, we found suppression of gluconeogenic gene expression and reduced CREB phosphorylation in hepatocyte cell lines treated with interferons. The impact of reduced gluconeogenic gene expression in the liver was seen when infected mice were less able to convert pyruvate, a gluconeogenesis substrate, to the same extent as uninfected mice. Infected mice also showed evidence of reduced systemic and hepatic insulin sensitivity. Similarly, in humans with TB, we found that changes in a metabolite-based signature of insulin resistance correlates temporally with successful treatment of active TB and with progression to active TB following exposure. These data support the hypothesis that TB drives interferon-mediated alteration of hepatic metabolism resulting in reduced gluconeogenesis and drives systemic reduction of insulin sensitivity. Tuberculosis (TB) is a worldwide disease with a substantial proportion of undiagnosed cases. Control of TB is mediated by a protective cellular immune response which is also chronic, inflammatory and systemic. Chronic inflammation can disrupt metabolism and compromise the organs key to maintaining health–such as the liver. The extent to which pulmonary TB can disrupt the metabolic function of the liver is ill defined. We have used a mouse model of pulmonary TB to examine the changes occurring in the liver when immunity is first being expressed in the lung. We found that pulmonary TB leads to upregulation of immune-related signalling pathways in liver cells and that TB infected mice have altered glucose metabolism. Reanalysing published metabolic data from humans, we find that a metabolic signature associated with insulin resistance separates those with TB from healthy subjects and alters with time to progression and resolution of TB, thereby indicating glucose metabolism disruption occurs during TB in humans. These data are important because we show that TB disrupts liver glucose metabolism, and this is critical to understanding the interplay between TB and metabolic disease.

Inhibition of leukotriene‐B4 signalling‐mediated host response to tuberculosis is a potential mode of adjunctive host‐directed therapy

Ly6G+Granulocytes-derived IL-17 limits protective host responses and promotes tuberculosis pathogenesis

The uncharted territory of host-pathogen interaction in tuberculosis

Toll-like receptor 4 signaling-mediated responses are critically engaged in optimal host protection against highly virulent Mycobacterium tuberculosis K infection

Human gene expression profiling identifies key therapeutic targets in tuberculosis infection: A systematic network meta-analysis

Can We Exploit Inflammasomes for Host-Directed Therapy in the Fight against Mycobacterium tuberculosis Infection?

Host and bacterial lipid metabolism during tuberculosis infections: possibilities to synergise host- and bacteria-directed therapies

Modern Clinical Mycobacterium tuberculosis Strains Leverage Type I IFN Pathway for a Proinflammatory Response in the Host

Anaerobe-enriched gut microbiota predicts pro-inflammatory responses in pulmonary tuberculosis

Synergistic role of Mycobacterium indicus pranii and Human Beta Defensin-2 as adjunctive therapy against Mycobacterium tuberculosis

Immunoinhibitory effects of anti-tuberculosis therapy induce the host vulnerability to tuberculosis recurrence

Induction of autophagy through CLEC4E in combination with TLR4: an innovative strategy to restrict the survival of Mycobacterium tuberculosis

Altered hepatic metabolic landscape and insulin sensitivity in response to pulmonary tuberculosis

Improving host-directed therapy for tuberculous meningitis by linking clinical and multi-omics data

Mucin Concentrations and Peripheral Airway Obstruction in Chronic Obstructive Pulmonary Disease

Elucidating the effect of pro and anti-inflammatory recombinant cytokines TNF-α and TGF-β in tuberculosis

Proteomics-based host-specific biomarkers for tuberculosis: The future of TB diagnosis

Cytokine Dynamics and Oxidative Stress in Host Cells Stimulated with Drug-Resistant and Sensitive Mycobacterium tuberculosis Isolates

Proteomic analyses of smear-positive/negative tuberculosis patients uncover differential antigen-presenting cell activation and lipid metabolism

Identification of Host-Targeted Small Molecules That Restrict Intracellular Mycobacterium tuberculosis Growth

Recent advances in understanding the human host immune response in tuberculous meningitis